The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study

ÇİÇEKLER, Hümeyra; BAYSAL, TAMER; KARATAŞ, Zehra; ŞAP, FATİH; Altın, Hakan

The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study

Zehra KARATAŞ, (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Pediatrik Kardiyoloji Bilim Dal, Konya, Türkiye)

Tamer BAYSAL, (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Pediatrik Kardiyoloji Bilim Dal, Konya, Türkiye)

FATİH ŞAP, (Sağlık Bakanlığı, Konya Eğitim ve Araştırma Hastanesi, Pediatri Kardiyoloji, Kliniği, Konya, Türkiye)

Hakan ALTIN, (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Pediatrik Kardiyoloji Bilim Dal, Konya, Türkiye)

Hümeyra ÇİÇEKLER (Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Biyokimya Anabilim Dalı, Konya, Türkiye)

Anadolu Kardiyoloji Dergisi

0 0

Yıl: 2013 Cilt: 13 Sayı: 4 Sayfa Aralığı: 350 - 356 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study

Öz:

Amaç: Bu çalışmanın amacı çocukluk döneminde romatizmal veya konjenital kapak hastalıklarının serum tenascin-C (TnC) ve total oksidan-antiok- sidan seviyeleri ile ilişkisini değerlendirmektir. Yöntemler: Yaşları 3-17 arasındaki 50 çocuk hasta (25 romatizmal kapak hastası, 25 konjenital kapak hastası) ile yaşça uyumlu 20 sağlıklı birey bu enine kesitli ve gözlemsel çalışmaya alındı. Tenascin-C, total anti-oksidan kapasite (TAC), total oksidan seviye (TOS) ve oksidatif stres indeks (OSİ) değerleri gruplar arasında karşılaştırıldı. Gruplar arası karşılaştırmalarda ANOVA ve Kruskal-Wallis testi kullanıldı. Bulgular: Romatizmal kalp hastalığı grubunun TnC düzeyleri [ortanca 9.09 (0.94-46.30) ng/mL] konjenital ve kontrol gruplarından yüksek bulundu [sırasıyla ortanca 2.97 (0.66-11.80) ng/mL, p<0.01; 4.72±1.77 ng/mL, p<0.05]. Ancak konjenital grup ile kontrol grubunun TnC düzeyleri arasında ista- tistiksel olarak anlamlı bir farklılık saptanmadı. Gruplar arasında TAC, TOS ve OSI değerleri açısından da farklılık saptanmadı. Tenascin-C düzeyi ile TOS ve OSI arasında da korelasyon saptanmadı. Sonuç: Tenascin-C, romatizmal kapak hastalıkları ile konjenital kapak hastalıkları ayırıcı tanısında bir biyokimyasal marker olarak kullanılabilir. Romatizmal ve konjenital kapak hastalıklarında oksidan ve antioksidan sistemlerin denge içinde olması, çocukluk döneminde oksidatif stresin romatizmal kalp hastalığı etyopatogenezinde belirgin rolü olmadığını düşündürmektedir.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Tenascin-C ve oksidatif stresin romatizmal ve konjenital kalp kapak hastalığındaki rolü: Gözlemsel bir çalışma

Öz:

Objective: The aim of this study was to evaluate the association of tenascin-C (TnC) and total oxidant-antioxidant status to rheumatic or con- genital heart valve diseases (HVD) in pediatric patients. Methods: Fifty pediatric patients (25 rheumatic HVD patients and 25 congenital HVD patients) and 20 healthy age-matched control subjects, aged 3-17 years, were enrolled in this observational and cross-sectional study. Serum total antioxidant capacity (TAC), total oxidant status (TOS), oxidative stress index (OSI) and TnC levels were compared among the groups. ANOVA and Kruskal-Wallis tests were used for statistical analysis. Results: Serum TnC level of the patients with rheumatic HVD [median 9.09 (0.94-46.30) ng/mL] was significantly higher than both congenital HVD and control groups [median 2.97 (0.66-11.80) ng/mL; p<0.01, 4.72±1.77 ng/mL; p<0.05, respectively]. However, there was no statistically significant difference between the congenital and control groups in terms of serum TnC level. The levels of serum TAC, TOS and OSI were found to be statistically similar in all groups. In addition, there were no correlations between the level of TnC, and TOS and OSI. Conclusion: Tenascin-C can be used as a biochemical marker in the differential diagnosis of rheumatic and congenital HVD. As the oxidant and antioxidant systems were found to be in equilibrium in rheumatic and congenital HVD, oxidative stress can be thought not to have a marked role in the etiopathogenesis of rheumatic HVD during childhood.

Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Lincoln J, Yutzey KE. Molecular and developmental mechanisms of congenital heart valve disease. Birth Defects Res A Clin Mol Teratol 2011; 91: 526-34. [CrossRef]
2. Davutoğlu V, Çelik A, Aksoy M. Contribution of selected serum inflammatory mediators to the progression of chronic rheumatic valve disease, subsequent valve calcification and NYHA functional class. J Heart Valve Dis 2005; 14: 251-6.
3. Gölbaşı Z, Uçar O, Keleş T, Şahin A, Çağlı K, Çamsarı A, et al. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation. Eur J Heart Fail 2002; 4: 593-5. [CrossRef]
4. Tani LY. Rheumatic Fever and Rheumatic Heart Disease. In: Allen HD, Driscoll DJ, Shaddy RE, Feltes TF, editors. Moss and Adam’s Heart Disease in Infants, Children and Adolescents, 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2008. p.1256-80.
5. Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol 2010; 30: 17-23. [CrossRef]
6. Fan H, Liu W, Yan P Pathological observation and immunohistochemistry study of Type I, III, IV collagen in mitral valve and cardiac interstitium of rheumatic disease. Zhonghua Yi Xue Za Zhi 1996; 76: 183-6.
7. Udalova IA, Ruhmann M, Thomson SJ, Midwood KS. Expression and immune function of tenascin-C. Crit Rev Immunol 2011; 31: 115-45. [CrossRef]
8. Golledge J, Clancy P Maguire J, Lincz L, Koblar S. The role of tenascin C in cardiovascular disease. Cardiovasc Res 2011; 92: 19-28. [CrossRef]
9. Jian B, Jones PL, Li Q, Mohler ER 3rd, Schoen FJ, Levy RJ. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 2001; 159: 321-7. [CrossRef]
10. Satta J, Melkko J, Pöllänen R, Tuukkanen J, Pääkkö P Ohtonen P et al. Progression of human aortic valve stenosis is associated with tenascin-C expression. J Am Coll Cardiol 2002; 39: 96-101. [CrossRef]
11. Jiang L, Wei XF, Yi DH, Xu P Liu H, Chang Q, et al. Synergistic effects of cyclic strain and Th1-like cytokines on tenascin-C production by rheumatic aortic valve interstitial cells. Clin Exp Immunol 2009; 155: 216-23. [CrossRef]
12. Chiavaroli V, Giannini C, De Marco S, Chiarelli F, Mohn A. Unbalanced oxidant-antioxidant status and its effects in pediatric diseases. Redox Rep 2011; 16: 101-7. [CrossRef]
13. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999; 19: 1218-22. [CrossRef]
14. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84. [CrossRef]
15. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38:1103-11. [CrossRef]
16. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37:112-9. [CrossRef]
17. Rabus M, Demirbağ R, Sezen Y, Konukoğlu O, Yıldız A, Erel O, et al. Plasma and tissue oxidative stress index in patients with rheumatic and degenerative heart valve disease. Turk Kardiyol Dern Ars 2008; 36: 536-40.
18. Chiu-Braga YY, Hayashi SY, Schafranski M, Messias-Reason IJ. Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP). Int J Cardiol 2006; 109: 275-6. [CrossRef]
19. Guidelines for the diagnosis of rheumatic fever. Jones criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA 1992; 268: 2069-73. Erratum in: JAMA 1993; 269: 476. [CrossRef]
20. Rheumatic fever and rheumatic heart disease. World Health Organ Tech Rep Ser 2004: 23: 1-122.
21. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol 2010; 55: 2789-800. [CrossRef]
22. Freed LA, Benjamin EJ, Levy D, Larson MG, Evans JC, Fuller DL, et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study. J Am Coll Cardiol 2002; 40: 1298-304. [CrossRef]
23. Harma MI, Harma M, Erel O. Measuring plasma oxidative stress biomarkers in sport medicine. Eur J Appl Physiol 2006; 97: 505-8. [CrossRef]
24. Yavuz T, Nisli K, Öner N, Dindar A, Aydoğan U, Ömeroğlu RE, et al. Long term follow-up results of 139 Turkish children and adolescents with rheumatic heart disease. Eur J Pediatr 2008; 167: 1321-6. [CrossRef]
25. Wu MH, Lue HC, Wang JK, Wu JM. Implications of mitral valve prolapse in children with rheumatic mitral regurgitation. J Am Coll Cardiol 1994; 23: 1199-203. [CrossRef]
26. Chen MC, Chang JP Liu WH, Yang CH, Chen CJ, Fang CY, et al. Increased serum oxidative stress in patients with severe mitral regurgitation: a new finding and potential mechanism for atrial enlargement. Clin Biochem 2009; 42: 943-8. [CrossRef]
27. Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 2007; 11: 1369-84. [CrossRef]
28. Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 2001; 30: 203-7. [CrossRef]
29. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000; 218: 235-59. [CrossRef]
30. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol 2004; 9: 517-25.
31. Aziz SM, Toborek M, Hennig B, Mattson MP Guo H, Lipke DW. Oxidative stress mediates monocrotaline-induced alterations in tenascin expression in pulmonary artery endothelial cells. Int J Biochem Cell Biol 1997; 29: 775-87. [CrossRef]
32. Oran B, Atabek E, Karaaslan S, Reisli Y, Gültekin F, Erkul Y. Oxygen free radicals in children with acute rheumatic fever. Cardiol Young 2001; 11: 285-8. [CrossRef]
33. Üner A, Sal E, Doğan M, Şanlı FM, Açıkgöz M, Cemek M, et al. Investigation of oxidant and antioxidant pathway changes in acute rheumatic fever. Acta Cardiol 2010; 65: 53-7. [CrossRef]
34. Kurban S, Mehmetoğlu I, Oran B, Kıyıcı A. Homocysteine levels and total antioxidant capacity in children with acute rheumatic fever. Clin Biochem 2008; 41: 26-9. [CrossRef]
35. Shanidze E, Zhvania M. Activity of lipid peroxidation processes and the condition of antioxidative defense system in children with rheumatic fever. Georgian Med News 2005; 127: 38-40.
36. Ahmed MI, Gladden JD, Litovsky SH, Lloyd SG, Gupta H, Inusah S, et al. Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction >60%. J Am Coll Cardiol 2010; 55: 671-9. [CrossRef]

APA	KARATAŞ Z, BAYSAL T, ŞAP F, Altın H, ÇİÇEKLER H (2013). The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study. , 350 - 356.
Chicago	KARATAŞ Zehra,BAYSAL TAMER,ŞAP FATİH,Altın Hakan,ÇİÇEKLER Hümeyra The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study. (2013): 350 - 356.
MLA	KARATAŞ Zehra,BAYSAL TAMER,ŞAP FATİH,Altın Hakan,ÇİÇEKLER Hümeyra The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study. , 2013, ss.350 - 356.
AMA	KARATAŞ Z,BAYSAL T,ŞAP F,Altın H,ÇİÇEKLER H The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study. . 2013; 350 - 356.
Vancouver	KARATAŞ Z,BAYSAL T,ŞAP F,Altın H,ÇİÇEKLER H The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study. . 2013; 350 - 356.
IEEE	KARATAŞ Z,BAYSAL T,ŞAP F,Altın H,ÇİÇEKLER H "The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study." , ss.350 - 356, 2013.
ISNAD	KARATAŞ, Zehra vd. "The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study". (2013), 350-356.

APA	KARATAŞ Z, BAYSAL T, ŞAP F, Altın H, ÇİÇEKLER H (2013). The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study. Anadolu Kardiyoloji Dergisi, 13(4), 350 - 356.
Chicago	KARATAŞ Zehra,BAYSAL TAMER,ŞAP FATİH,Altın Hakan,ÇİÇEKLER Hümeyra The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study. Anadolu Kardiyoloji Dergisi 13, no.4 (2013): 350 - 356.
MLA	KARATAŞ Zehra,BAYSAL TAMER,ŞAP FATİH,Altın Hakan,ÇİÇEKLER Hümeyra The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study. Anadolu Kardiyoloji Dergisi, vol.13, no.4, 2013, ss.350 - 356.
AMA	KARATAŞ Z,BAYSAL T,ŞAP F,Altın H,ÇİÇEKLER H The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study. Anadolu Kardiyoloji Dergisi. 2013; 13(4): 350 - 356.
Vancouver	KARATAŞ Z,BAYSAL T,ŞAP F,Altın H,ÇİÇEKLER H The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study. Anadolu Kardiyoloji Dergisi. 2013; 13(4): 350 - 356.
IEEE	KARATAŞ Z,BAYSAL T,ŞAP F,Altın H,ÇİÇEKLER H "The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study." Anadolu Kardiyoloji Dergisi, 13, ss.350 - 356, 2013.
ISNAD	KARATAŞ, Zehra vd. "The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study". Anadolu Kardiyoloji Dergisi 13/4 (2013), 350-356.